In-hospital experience with multiprogrammable implantable antitachycardia/antifibrillation devices

Area of Science:

• Cardiology
• Biomedical Engineering

Background:

• Refractory malignant ventricular tachycardia (VT) and fibrillation (VF) pose significant risks.
• Automatic internal defibrillators (AIDs) are crucial for managing these arrhythmias.
• The role of multiprogrammable AIDs with antitachycardia pacing (ATP) requires further clinical evaluation.

Purpose of the Study:

• To assess the clinical safety and utility of multiprogrammable AIDs with and without ATP in patients with refractory VT/VF.
• To evaluate the impact of device programmability on arrhythmia detection and therapy delivery.

Main Methods:

• Implantation of 60 multiprogrammable AIDs in patients with refractory VT/VF.
• Individual adjustment of VT/VF detection parameters based on arrhythmia type and incidence.
• Programmability allowed for pre-discharge device function verification.

Main Results:

• No increased surgical or postoperative risks associated with complex AID systems.
• Tailored detection parameters and reduced shock energy for VT vs. VF.
• Antitachycardia pacing was well-tolerated in 68% of eligible patients.
• Device programmability facilitated verification of correct tachyarrhythmia control decisions.

Conclusions:

• Multiprogrammable AIDs with flexibility in programming are clinically safe and useful for managing malignant ventricular arrhythmias.
• Further long-term studies are needed to confirm persistent efficacy and safety.
• Individualized programming enhances the therapeutic potential of AIDs.